Investigation of clinical efficacy of Enzalutamide and its predictive factors in CRPC patients
Not Applicable
- Conditions
- castration resistant prostate cancer
- Registration Number
- JPRN-UMIN000015996
- Lead Sponsor
- Keio University School of Medicine
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- Male
- Target Recruitment
- 50
Inclusion Criteria
Not provided
Exclusion Criteria
1)Severe cardiac function disorders, hepatic function disorders, renal function disorders, infectious disease or hematopoietic disorders 2)Hypersensitivity to study medication 3)History of seizure or any condition that may predispose to seizure 4)Age <20 years 5)History of treatment with Enzalutamide, Abiraterone or chemotherapy 6)Patients whom the investigator judges inappropriate for the study
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method SMAC, CBC, serum PSA, cytokines, androgens, Lipid metabolism. Bone markers, QoL assessment PSA-PFS
- Secondary Outcome Measures
Name Time Method